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Interaction of Tamm—Horsfall protein with bacterial extracts. Crude
extracts of uropathic Escherichia coli have been reported to inhibit the
binding of human Tamm—Horsfall protein (THP) to homologous and
heterologous anti-THP antibody in immunoassays. This phenomenon
was believed to be due to immunologic cross reactivity between THP
and the bacterial antigens for the same antibody. Our attempts to
further purify and characterize these "cross reactive" antigens with ion
exchange and molecular sieve chromatography were unsuccessful.
When purified anti-THP antibody was conjugated to sepharose beads
forming an immunoadsorption column capable of isolating THP and
cross reactive antigens from solution, the bacterial extracts did not
react with the affinity column. However, binding between THP and the
bacterial extracts and between THP and whole bacteria were demon-
strated. These findings suggest that the cross reactivity seen in the
immunoassays is caused by the interaction between the bacterial
extracts and THP, and is not representative of true immunologic cross
reaction for a common antibody.
Tamm—Horsfall protein (THP) is a urinary glycoprotein that
has been implicated in the pathogenesis of tubulointerstitial
nephritis (TIN) associated with obstructive uropathies and
vesicoureteral reflux (VUR) [1, 21. THP appears to initiate the
development of TIN by inducing autoimmunity when it is
exposed to the immune system as a consequence of obstruction
or VUR [3—5]. Bacteriuria often complicates urinary tract
obstruction and may contribute to the development of TIN by
enhancing the autoimmune response to THP. This could occur
if the bacteria possessed antigens which cross reacted with THP
or through an adjuvant effect of the bacteria.
Fasth et a! [61 have shown that antigens derived from
Escherichia co/i inhibit the binding of THP to specific anti-THP
antibody and proposed that these bacterial extracts immuno-
logically cross react with THP. The present studies were
undertaken to further define the specifics of the inhibition and to
characterize the components of the bacterial extracts which
may cross react with THP. In addition we examined the
possibility that interactions among the various components in
the assay system, other than immunologic cross reactivity,
were responsible for the inhibition. Cross reactive components
could not be isolated by affinity chromatography with THP
antibody immunosorbent, but binding between THP and the
bacterial extracts could be shown. Our data suggest that the
putative cross reactivity seen in the immunoassay is caused by
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interaction between THP and the bacterial extracts rather than
between the extracts and THP antibody.
Methods
Tamm—Horsfal/ protein (THP)
THP was prepared from pooled human urine, as described by
Fletcher, Neuberger and Ratcliffe [71, by repeated precipitation
in 0.58 M NaC! followed by extensive dialysis against distilled
water. The human (H)THP was stored in the lyophilized state at
4°C. The purity of the preparation was checked by polyacryl-
amide gel electrophoresis in sodium dodecyl sulfate (SDS).
Phosphorylase b, bovine serum albumin, ovalbumin, carbonic
anhydrase, soybean trypsin inhibitor and a-lactalbumin were
used as molecular weight standards (Pharmacia Fine Chemi-
cals, Piscataway, New Jersey, USA).
Bacterial antigens
Veronal buffer extracts (VE) of E. co/i 014:K7(L):NM
(ATCC# 19110), K/ebsie/la oxytoca and an untypable E. co/i
(ECY9) were prepared according to Holmgren et al [81 as
modified by Kaijser, Jodal and Hanson [9]. Heat extracts (HE)
of these bacteria were also prepared [8] as were antigenic
extracts ofAspergi/lusfumigatus [10] and Legione/la pneumo-
phi/ia [11]. Ribonuclease A (Sigma, St. Louis, Missouri, USA)
and mannan purified from Candida were used for testing the
specificity of the assays.
Antisera
Rabbit anti-HTHP was raised in New Zealand white rabbits
given a single subcutaneous injection of 150 ig HTHP in
complete Freund's adjuvant (CFA), followed by three weekly
i.v. injections of 50 sg of HTHP in water. The rabbits were bled
twice weekly for three weeks beginning two weeks after the
final HTHP boost. These sera produced a single precipitin band
against HTHP by agar gel diffusion (Ouchterlony). Immuno-
globulin fractions were prepared by ammonium sulfate precip-
itation.
Rabbit antisera to VE of E. co/i 014 were raised by injecting
New Zealand white rabbits subcutaneously with 0.8 mg of
crude VE in CFA, followed by three weekly subcutaneous
injections with 0.4 mg VE in incomplete Freund's adjuvant and
a final boost with 25 tg yE. Sera were obtained two and four
weeks thereafter.
Rabbit antisera against A.fumigatus [10] and L. pneumophila
[11] were raised using established methods.
Human sera were obtained from healthy laboratory personnel
and from patients with obstructive uropathy or nephrolithiasis.
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Radiolabelling
Protein moieties were radiolabelled by the modified chioram-
me T method [10, 12]. The following reactants were prepared:
1251-HTHP(104 cpmlng) and '251-Staphylococcal protein A(104
cpm/ng).
Antibody determinations
Solid phase radioimmunoassay (SPRIA). Serum anti-HTHP
antibody levels were evaluated using a solid phase radio-
immunoassay previously developed by us [101. A sample was
considered positive if it bound '251-PA at a level more than 2 SD
above the mean bound by the normal panel, as described
previously [10].
Enzyme linked immunosorbent assay (ELISA). Serum anti-
body was also determined by an indirect ELISA procedure.
Microtiter plates were coated with antigen in water (for HTHP),
or phosphate buffered saline (PBS) for all other antigens, at 4°C
overnight. The wells were aspirated, washed three times with
PBS and blocked with 2% BSA-PBS. The plate was aspirated,
and antisera diluted in 2% BSA-PBS was added to the antigen
coated wells. After overnight incubation at 4°C, the plates were
washed three times with PBS. Alkaline phosphatase conjugated
anti-human IgG (Sigma) or anti-rabbit IgG (Cappel Laborato-
ries, Malvern, Pennsylvania, USA) diluted 1/1500 in 2% BSA/
PBS was added to each well and incubated for two hours at
37°C. The plate was again washed and p-nitrophenyl phosphate,
1 mg/mi in 0.05 M sodium carbonate, 0.001 M magnesium
chloride, 0.02% sodium azide, pH 9.8, was added. The plate
was incubated at 37°C to allow color development and then read
at 405 nm in an automated ELISA reader (Titertek Multiscan,
Flow Labs, McLean, Virginia, USA). A sample was considered
positive if its 0D405 was above that of the mean plus two SD of
a normal panel, except for anti-YE where an individual serum
sample was considered positive if its OD was above the mean
plus twice the SE for the total population assayed.
Correlation between individual levels of anti-THP and anti-
VE was examined by calculation of the product—moment cor-
relation coefficient (r) according to the formula:
—
(x1—X)(y1—Y)
r —
\/(x1 — X)2 (yj —
where x is one variable (0D405 for anti-THP) with mean , and
y is the other variable (0D405 for anti-YE) with mean 37.
Inhibition studies
Competitive radioimmunoassay (CSPRIA). A competitive
radioimmunoassay was employed to detect the level of HTHP
or cross reactive antigen in a sample [10, 13]. Briefly, rabbit
anti-HTHP IgG (50 sl at 10 tgIml) was adsorbed to polyvinyl
microtiter plate wells (Flow Labs). After washing and blocking
with BSA, 10 d of '251-THP (10 cpm in 1% BSA-PBS) and 40
d of test antigen in water (non-radioactive HTHP or bacterial
extract preparation) were added to the wells. After further
incubation (18 hrs at 4°C), the wells were aspirated, washed,
dried, cut from the plate, and counted for bound radioactivity.
The amount of HTHP or cross reactive antigen was determined
by comparison to a standard curve prepared by the serial
dilution of a known sample of HTHP that was run concomi-
tantly on each plate.
Competitive ELISA. Microtiter plates (Dynatech, Alexan-
dria, Virginia, USA) were coated with 200 pi of HTHP (32
sg/ml in distilled water) and incubated at 4°C for 18 hours. The
wells were then washed three times with 0.01 M borate buffered
saline (BBS), pH 8.6, and blocked with 5% BSA-BBS. Anti-
body (250 s1 anti-THP diluted 1/1000 in 5% BSA-PBS) and
antigen (250 sl of serially diluted THP or YE in water) or
control (water) were pre-incubated at 37°C for three hours and
then at 4°C for 18 hours. The antibody antigen mixtures (200 d
aliquots) were then added to the HTHP coated plate and
incubated for a further 18 hours at 4°C. The wells were
aspirated, washed and refilled with 200 d of horseradish
peroxidase—conjugated goat anti-rabbit IgG (Cappel Labs) di-
luted 1/1000 in 1% BSA/BBS. After two hours at 37°C, the wells
were aspirated, washed and refilled with o-phenylenediamine
(0.7 mg/ml in 0.1 M citric acid buffer, pH 5.0, containing 0.015%
hydrogen peroxide). Plates were wrapped in aluminum foil,
incubated at room temperature for one hour, and then read with
an automated ELISA reader at 492 nm.
To study the inhibition by YE of antigen—antibody systems
other than HTHP-anti-HTHP the competitive ELISA was
modified as follows: the initial coating antigen was prepared in
0.01 M sodium carbonate buffer, pH 9.6; alkaline phospha-
tase—conjugated goat anti-rabbit IgG (Cappel Labs) was used
instead of the peroxidase conjugate; p-nitrophenyl phosphate
was used as the substrate; and the absorbance was read at 405
nm.
Immunosorbent reagents
Sepharose 4B was activated with cyanogen bromide accord-
ing to the method of Cuatrecasas, Wilcheck and Anfinsen [14].
HTHP-Sepharose was prepared by a modification of Sela,
Wang and Edelman [15]. HTHP and activated Sepharose 4B (2
mg HTHP per ml of sepharose beads) were suspended in 0.1 N
sodium bicarbonate, pH 8.3, and gently shaken overnight at
4°C. The preparation was blocked with glycine for two hours at
room temperature, washed extensively with alternating solu-
tions of 0.1 N sodium bicarbonate, pH 8.3 and 0.1 M sodium
acetate, pH 4, and equilibrated with PBS for storage.
Affinity purified anti-HTHP was prepared by passage of the
sera of rabbits immunized to HTHP over a column of HTHP-
Sepharose by a modification of the method of Abbondanza,
Licastro and Serafini—Cessi [16]. A column of HTHP-Sepharose
was poured, washed with glycine/HC1 buffer (0.05 M glycine/
HC1, 0.05 M NaC1, pH3.0), and then re-equilibrated with PBS.
Rabbit sera was diluted with an equal volume of PBS and added
to the column. The column was washed with PBS until no
protein was detected in the effluent. The affinity—purified anti-
HTHP antibody was then eluted from the column with glycine/
HC1, dialyzed, and lyophilized.
Rabbit anti-HTHP coupled Sepharose was prepared by a
modification of established procedures [14, 17]. Five ml of
cyanogen bromide activated sepharose suspended in 5 ml of 0.1
M sodium bicarbonate, 0.5 M NaC1, pH 8.3, was stirred gently
for 24 hours at 4°C with 2.2 ml of affinity—purified anti-HTHP
antibody (10 mg/mI). The beads were blocked with 0.05 M
ethanolamine for five minutes, washed with buffers of alternat-
ing pH (bicarbonate, pH 8.3, and acetate, pH 4.0) until no
protein was detected in the washes, and then equilibrated with
PBS. A control immunosorbent column was prepared in the
1 2 3 4 5 6 7same way using sera from rabbits which were not immunized.
The effluents and eluents were examined by SPRIA and/or
optical density measurement.
Studies of interactions between THP and VE
1.) To glass tubes containing 0.5 ml of HTHP (200 g/ml) and
'251HTHp (132,000 cpm) in 4 m phosphate buffer, pH 7.0,
was added 0.5 ml of distilled water containing phytohemag-
glutinin (PHA) or E. coli 014 YE (1000 gig/mi and 200 g/ml).
Mixtures were incubated for four hours at 37°C, one hour at 4°C
and then washed onto 0.45 m filters in a sampling manifold
with 2 m phosphate buffer. Filters were dried and counted for
radioactivity.
2.) To micro-centrifuge tubes (0.5ml size) previously coated
with 1% crystalline BSA in PBS was added 125 pJ '251-HTHP
(468,000 cpm) and 125 1 of water, PHA or YE. Concentrations
and buffer conditions were the same as described in #1 above.
The mixtures were incubated for one hour at 37°C, 18 hours at
4°C, and then centrifuged (2000 xg for 45 minutes). Duplicate 50
1.d aliquots of each supernatant were counted for radioactivity.
3.) Broth cultures of E. co/i (014, ECY9, or fecal isolates
obtained from healthy control subjects) were prepared by
inoculating trypticase soy broth (TSB) with a single agar—grown
colony of each, and incubating the TSB for six or 18 hours at
37°C. Cultures were washed and resuspended (2 m potassium
phosphate buffer, 31 m sodium chloride, pH 7.4) at 5 X io E.
co/i/mi, as determined by standard absorbance curves (550nm).
'251-HTHP (lOs cpm) was added to aliquots of E. co/i (5 x iø,
iO, 108, or io per ml) in BSA-coated glass tubes which were
then incubated at 37°C for one hour and then overnight at 4°C.
After centrifugation the pelleted bacteria were resuspended,
washed twice in 2 m phosphate buffer, resuspended and
transferred to clean tubes, centrifuged, and the pellets counted
in a gammacounter (Packard, Downers Grove, Illinois, USA).
Bacteria—free controls included PHA (350 Lg/ml), trichloracetic
acid (10%), anti-THP and buffer alone.
4.) To the wells of micro-ELISA plates 100 pA of the following
reactants, separated by PBS washes, were added sequentially:
HTHP (10 to 32 g/ml in water) or water alone (control) for 18
hours at 4°C; 1% BSA-PBS for two hours (no wash); YE (0.01
to 5.0 mg/mI in PBS) for five hours; rabbit anti-YE serum
(1:1000 in 1% BSA-PBS) for 18 hours at 4°C; alkaline
phosphatase—conjugated goat anti-rabbit IgG (1:1500 in 1%
BSA-PBS) for two hours at 37°C; and p-nitrophenyl phosphate
(1 mg/mI in carbonate buffer, pH 9.8) for >one hour at 37°C.
Absorbance was measured at 405 nm.
Immunodiffusion
Agar gel diffusion was performed with Ouchterlony plates by
established methods.
Po/yacrylamide gel electrophoresis
Yeronal extracts were characterized by polyacrylamide slab
gel electrophoresis (PAGE) in the presence of SDS [18]. Sam-
ples were routinely boiled for five minutes before addition to the
gel. Protein—containing subunits were identified by Coomassie
blue staining.
Results
PAGE
HTHP ran as a single protein band corresponding to a
molecular weight of approximately 80,000. The protein contain-
ing constituents of the veronal buffer extract of the bacteria
(VE) were also characterized by PAGE. Figure 1 shows an
example of the complex pattern of protein—containing subunits
found for the VE of E. co/i 014.
Immunodjffusion
Single precipitin bands were formed when HTHP (100 ,ag/ml)
was tested against the anti-HTHP antisera raised in rabbits.
HTHP did not form a precipitin band with any of the anti-YE
antisera raised by immunizing rabbits with the veronal buffer
extracts. YE formed three or more precipitin bands with the
anti-YE antisera. YE did not form precipitin bands when tested
against anti-HTHP antibody in whole sera or against the affinity
purified anti-HTHP antibody.
Inhibition of THP anti-THP binding by VE
Prior to testing in the inhibition systems the rabbit anti-HTHP
antisera were tested in the direct SPRIA and shown to be of
high titer, with antibody detectable in dilutions down to 10—6.
The ability of fluid phase HTHP to inhibit the binding
between rabbit antibody to HTHP and solid phase HTHP, as
determined by the competitive ELISA, is shown in Figure 2.
Fifty percent inhibition occurred with 2.5 x l0 mg HTHP per
ml (2.2 x 10-10 moles THP/liter) and 95% inhibition with 1 x
i0 mg HTHP/ml. We confirmed that crude YE of E. coli 014
was also inhibitory, but considerably less potent than HTHP. In
this example, 50% inhibition of HTHP-anti-HTHP binding
occurred with VE at 3 mg/ml, and 75% at 10 mg/ml. The heat
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Fig. 1. SDS PAGE stained with Coomassie blue. Lanes 1, 2 and 6 are
YE of E. coli 014; 3 and 7 are ovalbumin; 4 is HTHP; and 5 is BSA.
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Test antigen concentration, mg/mi
_
_ Anti-<
HTHP 4—Test antigen
Test antigen concentration, mg/mi
THP added
to colum&'
THP in
effluent
THP adsorbed
onto column
THP elated
from column
Trial 1 0.1 mg 6% 94% 8%
Trial 2 2.0 mg 18% 82% 30%
Trial 3 1.0 mg 22% 78% 29%
HE a THP present in solution measured by optical densityb Column size was 5 ml of packed anti-THP Sepharose
that of the ELISA, the dose response inhibition curves for VE
and HE were comparable to those determined by ELISA. For
17 total determinations, the mean 50% inhibition concentration
(± 1 SE) for HTHP was 7.0 2.4 x l0' mg/ml, as compared to
4.2 0.9 mg/mI for VE (1/6000 relative potency by weight).
Parallel curves of inhibition were seen for the VE preparations
10 from the three different bacterial strains.
Unrelated antigens were also tested in this system. Ribonu-
clease A and A. fumigatus somatic antigen resulted in no
inhibition and 10% inhibition respectively in the CSPRIA at a
concentration of 10 mg/ml. Concanavalin A, a mitogen which
binds to THP, caused 40% inhibition in the competition ELISA
at I mg/ml.
Affinity purification of anti-THP
A total of 22 mg of affinity purified anti-HTHP antibody was
obtained by passing 60 ml of antiserum over a column of HTHP
coupled sepharose and eluting with 0.05 M glycine/HC1, pH 2.3.
The affinity purified antibody gave a single band on immunodif-
fusion against HTHP. SPRIA was able to detect anti-HTHP
antibody in solutions of the affinity purified protein at concen-
trations as low as 10 ng/ml.
Affinity chromatography of THP
The affinity purified anti-HTHP was used to prepare an
anti-HTHP sepharose immunosorbent column. Affinity chro-
matography was performed on samples of HTHP of differing
concentrations and volumes. The results of three immunoad-
sorption runs of HTHP are summarized in Table 1. Seventy—
eight to 94% of the HTHP was adsorbed from the samples by
the column as determined by comparision of optical density of
the effluent (corrected for dilution) with that of the pre-column
sample. Immunologically active HTHP was quantitatively re-
covered in the eluent, as determined by SPRIA.
Affinity chromatography of VE
Three trials of immunoadsorption of VE were performed: one
using a column technique and two a batch technique. Each trial
was followed by an immunoadsorption of I-ITHP as a control to
ensure that antibodies on the column were not saturated, and
that they had a large capacity to adsorb antigen. The results of
the affinity chromatography of YE are summarized in Table 2.
In no case did immunoadsorption of YE result in decreased
cross reactivity of the effluent in the SPRIA. The optical density
of the effluent was equal to that of the YE prior to its passage
over the column, indicating that the anti-THP antibody conju-
gated to the column did not bind a significant amount of YE
protein.
antiHuman HTHP >— HRPC—anti—lg
- THP Test
antigen
0.5
0.4
E. coli 014
Table 1. Affinity chromatography of THP
0.3
0.2
50%
inhibition
0.1
J)
+1
I
Fig. 2. Competition ELISA showing inhibition of anti-THP binding to
solid phase HTHP by veronal extract (VE) (s), heat extract (HE) (A),
and by fluid phase HTHP (•). HRPC is horseradish peroxidase.
VE
Human THP
0 1O 10—6 i05 io io 10—2 1O 100
4
(I)
+1
cn
0
.00II-
a-U
Fig. 3. Competition SPRIA showing inhibition of binding of radio/abel-
led THP to solid phase anti-THP antibody by VE (5, HE (A), and by
unlabelled THP (•).
extract (HE) of E. coli 014 was less inhibitory (28% with 10
mg/mi) than YE.
Inhibition by HTHP and VE were also detected by CSPRIA
in which the anti-HTHP immunoglobulin fraction was immobi-
lized to the solid phase. In the example shown in Figure 3, 50%
inhibition occurred with 1.5 x iO mg HTHP/ml, 1.5 mg YE/mI
and 8 mg HE/mI. Although the sensitivity of this assay to detect
nanogramlml concentrations of HTHP was marginally less than
0 10 10_6 1o° iO i0 10—2 10_i 100 10
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Quantity of VE
incubated with
immunosorbent
Pre-column
inhibitiona
Post-column
inhibitiona P value
Trial 1 250 mg 38% 44% 0.50
Trial 2 225 mg 45% 34% 0.15
Trial 3 20 mg 20% 29% 0.01
After reacting VE with the column, repeated attempts were
made to elute from the column any material which may have
bound to it. No protein was detectable in the eluent by
spectrophotometry, and no material was recovered from the
eluents after lyophilization.
Correlation between anti-VE and anti-THP titers
Anti-VE antibody titers were studied during the course of
immunization with THP. We compared the direct binding
ability of sera from 35 different rabbits (five challenged with
crude VE in CFA, six challenged i.v. with endotoxin—free
rabbit THP, six challenged i.v. with endotoxin—containing
human THP, and 15 normal unchallenged controls) by ELISA.
The results showed that all five of the anti-VE sera bound to
solid phase VE (absorbance >2.0 at 405 nm for 1:100 serum
dilution). However, only two of 12 sera, one each from the
endotoxin—free and the endotoxin—containing THP groups,
demonstrated binding to YE, as did two of 15 from the normal
control group (absorbance >1.0). Normal rabbit sera which had
VE antibody prior to immunization with THP did not demon-
strate any change in YE antibody titer as they went on to
produce high affinity anti-THP antibody after immunization. It
should be noted that the observed YE inhibition of THP/anti-
THP binding in the CSPRIA assay was unrelated to the con-
comitant presence of anti-VE in these anti-THP sera, since
inhibition by YE was consistently found for sera containing
anti-THP and no anti-VE.
Sera were also surveyed for the presence of anti-THP anti-
body by ELISA and by SPRIA. None of the rabbits immunized
with YE developed anti-THP antibodies. A survey of human
sera from 12 healthy laboratory personnel and 66 patients with
documented recurrent nephrolithiasis (46 males and 20 females)
also failed to show any correlation between anti-THP and
anti-YE. None of 12 normals tested by SPRIA for anti-THP
antibody were positive, while 12 of 66 (18%) patients were
positive. Two of 12 (17%) normals were positive for anti-VE by
ELISA while eight of 66 (12%) patients were positive. Only one
individual, a patient with a history of both urinary tract infec-
tion and nephrolithiasis, had antibody to both THP and YE (1 of
66; 2%).
The possibility of any correlation between the individual
levels of anti-THP and of anti-VE was examined statistically by
calculation of the correlation coefficient (r) using the individual
OD5 values from the anti-THP and anti-YE ELISAs, respec-
tively. The calculated r was 0.04, indicating no correlation
between levels of anti-THP and anti-VE,
E. coil ECY9
nnnn
PHA5x109 iO 108 io Buffer PHA5x1O9 i0 io io Buffer
only only Only Only
Fig. 4. Binding of '251-HTHP to whole E. coli cells. Each panel shows
the amount of '251-HTHP bound to the different E. coli strains as a
function of the concentration of bacteria in the incubation mixture.
Uropathic strains (E. coliOl4 and ECY9).
Direct interaction of VE and THP
Since we were unable to demonstrate any direct binding o2
VE to anti-THP, the potential of YE to aggregate, precipitate
and/or bind to THP itself was studied. Filtration and centrifu-
gation precipitation studies (Methods) showed that THP and YE
did not interact to form sufficiently large aggregates to pellet at
2000 g or to be retained on 0.45 jm filters. PHA, a lectin, was
able to produce filter retention of 98.3% of a solution of
'251-THP Distilled water resulted in filter retention of only 5%
of THP. YE resulted in filter retention of 8% of added '251-THP.
In the centrifugation procedure 84% of a solution of '251-THP
was precipitated by PHA. Addition of VE to the '251-THP did
not result in detectable loss of '251-THP from solution after
centrifugation.
Binding of HTHP to whole bacteria was however demon-
strated. Figure 4 shows the dose response for four isolates of E.
co/i, two of which were uropathic strains (E. coli 014 and
ECY9). E. coli 014 at 5 x i09 bacteria per ml bound 3462 cpm
of '251-THP. PHA was able to precipitate 30,000 cpm of
iodinated THP. A 1/100 dilution of rabbit antibody to H-THP
precipitated 12,000 cpm of '251-HTHP; a 1/500 dilution precip-
itated 6,000 cpm.
VE binding to THP and unrelated antigens
YE was found to bind directly to solid phase THP in a dose
related manner in the ELISA (Fig. 5A). Detectable YE binding
to THP coated ELISA plates was observed using solutions of
Table 2. Inhibition by VE of THP binding to anti-THP, before and
after passage of YE through immunoabsorbent column
E. coIl 014
3
a Samplesof YE before and after immunoadsorption were lyophilized
and reconstituted in the same buffer to 4 mg/mI. The results represent
the percent of '251-THP inhibited by YE from binding to anti-THP
antibody as determined by CSPRIA assay.
2
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E. coli 014 VE concentration, mg/mi
Fig. 5. A. Dose response curves showing binding of VE to solid phase
THP. Plates were coated with solutions of either 30 sgJm1 (•), 20 g/m1
(Li), 10 g/m1 (A) or no THP (I). YE binding to THP coated plates was
then ascessed by sequential addition of antibody to yE, alkaline—phos-
phatase conjugated goat anti-rabbit IgG, and p-nitrophenyl phosphate.
B. Dose response curves showing binding of YE to a variety of different
solid phase antigens. Plates were coated with aspergillus 20 sg/ml (0),
THP 30 tg/ml (Li), ovalbumin 50 jig/mI (s), mannan 2 jig/mi (•), BSA(•), and gelatin 3%.
VE in concentrations as low as 10 tg/ml. Furthermore, as the
concentration of solid phase THP adsorbed to the plate was
increased, the quantity of bound VE increased proportionately.
VE also bound to the solid phase, that is to the BSA itself, in the
absence of THP. Nevertheless, the binding of VE in the
presence of THP was significantly greater at all concentrations
studied.
The ability of YE to bind to other materials was also
examined using this ELISA technique (Fig. SB). When a crude
extract of A. fumigatus somatic antigen (at 20 jig/ml) was used
to coat the plates, higher YE binding was observed than with
the THP (32 jig/mI) coated plates. At 0.5 mg/ml YE the 0D405
for aspergillus coated plates was 0.95 and for THP coated plates
was 0.61; at 1 mg/mI YE the 0D405 for aspergillus coated plates
was 1.3 and for THP 0.97. Lesser amounts of YE were bound
by ovalbumin and by mannan, respectively, than by THP.
Again, VE bound to BSA in the absence of THP, whereas VE
did not bind to gelatin.
VE inhibition in non-THP systems
The possibility that YE might also inhibit immunoassays of
antigen—antibody systems other than THP-anti-THP was exam-
ined. Since YE bound to A. fumigatus antigen even better than
to THP, we tested the effect of YE on a competitive ELISA to
measure aspergillus antigen. Figure 6 shows that YE inhibits
the interaction of aspergillus antigen and anti-aspergillus anti-
body more strongly than it inhibits THP-anti-THP binding. YE
at a concentration of 0.5 mg/ml caused 50% inhibition of A.
fumigatus anti-A. fumigatus binding, as compared to the 4
mglml of YE required to produce 50% inhibition of THP
anti-THP bindng.
Discussion
YE does inhibit the binding of HTHP to anti-HTHP in the
competitive ELISA and in the competitive SPRIA. This finding
is consistent with the results of Fasth et al [6], who first
documented the phenomenon by ELISA. In both studies a
concentration of 4 mg/mI of VE was required to produce 50%
inhibition of binding of HTHP to HTHP antibody. Both of these
assays have an incubation period in which HTHP and YE are
exposed to each other, and essentially work by allowing the test
antigen to directly interfere, in some manner, with the binding
of HTHP to its antibody.
There are three possible mechanisms by which the antigen
tested, in this case YE, can interfere with the binding of HTHP
to its antibody. First, YE may compete with HTHP for the
binding sites on the Fab fragment of the anti-HTHP antibody.
This would constitute true immunologic cross—reactivity. Sec-
ond, YE may react with anti-HTHP antibody in a non-immun-
ologic manner. For example, it might bind to a constant region
of rabbit antibody causing the antibody to aggregate, or causing
blockade of the antigen binding sites. Third, YE may inhibit the
binding of HTHP to anti-HTHP by complexing with the HTHP
itself and preventing proper antigen exposure and subsequent
binding to the antibody.
If the explanation is consistent with cross reactivity for the
same antibody, then VE must be able to interact with anti-
HTHP antibody directly by binding to the Fab portion of the
antibody. The cross reactive antigens would then be able to be
adsorbed onto an immunoadsorption column which contains
anti-HTHP antibody. If, however, YE causes inhibition of
binding of HTHP to its antibody by interacting with HTHP
itself, then antibody bound to an affinity column would not
interact with YE.
The affinity chromatography column composed of affinity—
purified anti-HTHP antibody did not adsorb any cross reactive
activity from solutions of YE. Even after 250 mg of YE was
allowed to incubate with the column for a prolonged period, no
protein was adsorbed onto the column, nor was any material
able to be eluted from the column. Failure to remove cross
reactive materials by affinity chromatography suggests that the
inhibition does not arise from YE binding to anti-HTHP anti-
body.
As further evidence that YE and HTHP are not cross—reac-
tive, we were able to demonstrate that immunization with either
antigen did not affect antibody titers directed at the other. We
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found that animals immunized against VE did not develop
anti-HTHP antibody and that HTHP immunization did not
affect VE antibody levels. Furthermore, YE was inhibitory in
the HTHP anti-HTHP system whether or not the particular
anti-HTHP sera used had detectable anti-YE antibody. These
findings are inconsistent with cross reactivity between HTHP
and YE.
The most likely explanation for the inability to demonstrate
concurrent anti-HTHP and anti-YE in sera or to obtain an
extract of VE by affinity chromatography is that YE is inhibi-
tory in the SPRIA and ELISA by interfering with HTHP
directly. In this study YE directly bound to HTHP in the
ELISA titration experiments. Furthermore, HTHP bound to
the whole bacteria from which YE had been isolated.
We have shown that YE can bind directly to THP. In order to
demonstrate that this direct binding can cause inhibition in the
ELISA, we examined the effect of YE in an ELISA used to
measure A. fumigatus antigen. YE was a more potent inhibitor
of the A. fumigatus anti-A. fumigatus binding than of the THP
anti-THP binding. This finding corresponded to the higher
affinity of YE for solid phase A. fumigatus antigen than for
THP.
A variety of substances which are not antibodies are known
to react with THP. Serafini—Cessi [191 has shown that lectins
can bind to the carbohydrate moiety of THP. Leucoagglutinin
has also been shown to form a precipitin reaction with THP
[16]. Concanavalin A binds to THP and not to antibodies to
THP. Concanavalin A was shown in this study to be inhibitory
in the competition ELISA. Clearly, binding to THP is sufficient
to cause inhibition in this immunoassay. Concanavalin A has
also been reported to bind to A. fumigatus somatic antigens
[20]. This observation as well as our data which shows binding
of VE to A.fumigatus and inhibition by YE of the A.fumigatus
competition assay, suggests some similarities in the carbohy-
drate moieties of THP and A. fumigatus.
E. co/i contains pili which act as lectins [21, 221. PAGE
analysis shows that YE contains protein bands with similar
electrophoretic mobility to these pilar proteins [23, 24]. Pili
such as these, acting as lectins, could bind to THP and cause
inhibition of binding of THP to anti-THP, but would fail to be
adsorbed by the immunosorbent column since they do not bind
to anti-THP. Direct binding of THP and E. co/i is also suggested
by the finding that E. co/i with type 1 pili are trapped by THP in
normal urine [251. This entrapment is decreased by addition of
D-mannose. THP contains mannose in its carbohydrate chain, a
fact which may be responsible for its ability to bind E. co/i.
Also, our results are in agreement with Kuriyama and
Silverblatt [26] who suggested, based on their experiments, that
THP may bind to E. co/i type 1 pili, thereby interfering with the
binding of THP to THP antibody. In addition, they observed
impaired phagocytosis of THP coated E. co/i, and suggested
that this impairment might permit the development of persistent
infection. Thus, the interaction of THP with some E. co/i may
impair normal host defense mechanisms. In contrast, this same
interaction of THP with type 1 piliated E. co/i may prevent
these organisms from adhering to urinary epithelial cells and
protect the host from infection. Although the biological signif-
icance of the binding of THP to E. co/i has not yet been
definitively determined, current observations suggest both a
negative and positive effect on the upper and lower urinary
tract, respectively.
Although it appears that the veronal extracts of the strains of
E. coli tested do not actually cross react with THP for anti-THP
antibody, the possibility of other bacterial preparations truly
cross reacting with THP or other renal antigens still exists.
However, our results question the validity of using immunoas-
says as the sole criterion for reporting cross reactivity. Appar-
ent immunologic activity of a preparation in an immunoassay is
not synonymous with cross reaction.
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